louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05498337: Vital Pulp Therapy With Different Materials for Young Permanent Teeth
Official title: Clinical Evaluation of Different Treatment Modalities for Vital Pulp of Immature Permanent Molars
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Vital Pulp Therapy
Keywords: Alpexogenesis
MTA
Calcium hydroxide
Diode Laser
Lead sponsor: Mansoura University
Sponsor class: OTHER
First posted: 2022-08-12
Enrollment: 100
Sex: ALL
Minimum age (years): 7
Maximum age (years): 9
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will be conducted to:

Evaluate clinically and radiographically apexogenesis in immature permanent molars using:

1. Calcium Hydroxide.
2. MTA.
3. Laser.
4. Laser combined with MTA.

Detailed description: Calcium Hydroxide has been the most commonly utilized pulpotomy agent for vital pulp therapy. It is the earliest medicament employed in pulpotomy that possesses the ability to stimulate tertiary dentinogenesis. This is attributed to its high alkalinity after mixing with water. Calcium hydroxide has a high pH, and its dental use relates chiefly to its ability to stimulate mineralization and also to its antibacterial property.

Biocompatibility and sealing ability are the most important properties, which account for optimal healing response in vital pulp therapy. Unlike conventional materials, MTA has low solubility and maintains its physical integrity after placement. It has several desirable characteristics in terms of biocompatibility, bioactivity, hydrophilicity, radiopacity, sealing ability and low solubility.

Diode laser in a young permanent tooth with traumatically exposed pulp has proved to be an effective technique for Pulpotomy in an immature tooth. Therefore, the use of soft-tissue diode lasers can influence the treatment outcome and should be seen as a predicable tool for vital pulp therapy.

Eligibility criteria: Inclusion Criteria:

* Medically free
* Vital teeth

Exclusion Criteria:

* Medically compromised
* Chronic abscess
* Non-vital teeth

Primary outcomes:
measure: Root completion
timeFrame: one year
Secondary outcomes:
measure: Root lengthening and thickening
timeFrame: one year
Other outcomes:
measure: Clinical evaluation
timeFrame: one year
Locations:
Study officials:
affiliation: Mansoura University
name: Salwa M Awad, Professor
role: STUDY_DIRECTOR
References:
Clinical trial NCT00415337: Endobronchial Ultrasound Guided Transbronchial Lung Biopsy With or Without Guide Sheath in Lung Tumors and the Analysis of Echoic Patterns of Lung Tumors and Mediastinal Lymph Nodes, and the Association Between Diagnostic Yield of Transbronchial Lung Biopsy and EBUS Echoic Features.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Lung Neoplasms
Keywords: lung
neoplasm
bronchoscopy
ultrasonography
histology
Lead sponsor: Chang Gung Memorial Hospital
Sponsor class: OTHER
First posted: 2006-12-22
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Sampling method: PROBABILITY_SAMPLE
Study population: Patient with radiologically confirmed peripheral lung mass

Brief summary: 1. Endobronchial ultrasonography (EBUS) is useful in localizing peripheral lung lesions. The EBUS, further combined with the guide sheath (GS) technique, has been reported to increase the yield of transbronchial biopsy. However, there are no reports comparing the GS technique and the traditional EBUS technique in diagnosing the peripheral lung tumor.
2. Previous reports have revealed that several characteristic echoic patterns correlate well with the histopathological findings of benign and malignant lesions. Therefore, EBUS may also be useful in the differential diagnosis of malignant lesions of the lung.


Eligibility criteria: Inclusion Criteria:

* Patient with radiologically confirmed peripheral lung mass

Exclusion Criteria:

* Patient clinically not indicated for bronchoscopy exam within the abovementioned cohort

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Department of Thoracic Medicine, Chang Gung Memorial Hospital
Study officials:
affiliation: Chang Gung Memorial Hospital
name: Han-Pin Kuo, Chair
role: STUDY_CHAIR
References:
Clinical trial NCT06213337: Virtual Classroom Training and SMS Supported Interventions Improving Foot Care and Self-Efficacy
Official title: Evaluation of the Effectiveness of Virtual Classroom Training and SMS Supported Interventions in Improving Foot Care Behaviors and Foot Care Self-Efficacy of Diabetic Patients
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Diabetic Foot Ulcer
Keywords: diabetic foot
virtual systems
Short Message Service
Lead sponsor: Ondokuz Mayıs University
Sponsor class: OTHER
First posted: 2024-01-19
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The type of this research is a randomized controlled experimental study. The aim of the research is to determine the effectiveness of virtual classroom training and SMS support in improving foot care behaviour and foot care self-efficacy in diabetic patients.

The basic questions the research aims to answer are:

* Is virtual classroom training effective in improving foot care behaviour and foot care self-efficacy in diabetic patients?
* Are SMS-supported interventions effective in improving foot care behaviour and foot care self-efficacy in diabetic patients? Within the scope of the research, participants are expected to attend virtual classroom training and read the SMS sentences sent.

In order to examine the effects of virtual classroom training and SMS-supported interventions, researchers created a control group, a virtual classroom, an SMS support group, and an SMS-supported virtual classroom group.


Eligibility criteria: Inclusion Criteria:

* Reporting that you have internet, computer/smartphone access
* Becoming literate
* Ability to use the internet and mobile devices effectively
* Declaring that you are competent to use technology-based training
* Being between the ages of 18-55
* Diagnosis period of 1 year or more

Exclusion Criteria:

* Having a psychiatric/neurological disability that may prevent participation in the research
* Having any diagnosis of learning disability
* Having an existing foot ulcer
* Having a history of foot ulcers and amputation in the past
* Having severe vision problems/retinopathy
* Having severe hearing impairment

Primary outcomes:
measure: Development of foot care behavior in diabetic patients
timeFrame: within 3 months
measure: Development of foot care self-efficacy in diabetic patients
timeFrame: within 1 months
Secondary outcomes:
Other outcomes:
Locations:
city: Samsun
country: Turkey
facility: Ondokuz Mayıs University
state: Atakum
Study officials:
affiliation: Hitit University
name: Burak Arslan, Lecturer
role: PRINCIPAL_INVESTIGATOR
affiliation: Ondokuz Mayıs University
name: Afitap Özdelikara, Assoc. Prof.
role: STUDY_DIRECTOR
References:
Clinical trial NCT01918137: The Effect of a Deep-fried Chocolate Bar or Porridge on Cerebral Blood Flow
Official title: A Randomised Trial of Effect of Deep-fried Chocolate Bar and Porridge Upon Cerebrovascular Reactivity in Healthy Adult Volunteers
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Effect on Cerebrovascular Reactivity
Lead sponsor: NHS Greater Glasgow and Clyde
Sponsor class: OTHER
Collaborators: name: University of Glasgow
First posted: 2013-08-07
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The deep fried chocolate bar is a snack that the international community strongly associates with Scotland. It has previously been cited as being "a symbol of all that is wrong with the high-fat, high-sugar Scottish diet". Despite the snack's reputation, no medical research has been performed to examine the effects of consuming a deep fried chocolate bar on the human body.

In contrast to the deep fried chocolate bar, porridge has been shown to reduce the risk of cardiovascular disease, but its effect on cerebral blood flow has yet to be directly assessed.

This study will focus on the potential (patho)physiological cerebrovascular effects of the deep fried chocolate bar and porridge. The research question to be addressed in this study is "Does eating a deep fried chocolate bar or bowl of porridge induce changes in cerebral blood flow and cereborvascular reactivity in healthy adults?"

To assess the acute effects on eating either food on blood flow through the largest artery in the brain, the investigators will give healthy volunteers one regular-sized deep-fried chocolate bar or a bowl of porridge. Blood flow through the largest artery in the brain will be assessed using simple ultrasounds tests. The investigators aim to recruit 24 volunterrs who will visit twice, consuming a different food on each visit.


Eligibility criteria: Inclusion Criteria:

* BMI between 18 and 30
* No regular medication
* Able to provide informed consent

Exclusion Criteria:

* Distaste for or contraindication to deep-fried chocolate bar or porridge ingestion
* inability to perform breath-hold

Primary outcomes:
measure: Change in breath hold index after ingestion of deep-fried chocolate bar compared with change after porridge ingestion
timeFrame: 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Glasgow
country: United Kingdom
facility: Western Infirmary
Study officials:
References:
Clinical trial NCT00228137: Randomised Controlled Trial PFC Versus CKS Total Knee Prostheses
Official title: A Prospective Randomized Double-Blind Study to Assess the Functional Differences Between the PFC and CKS Knee Prostheses
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Osteoarthritis, Knee
Lead sponsor: Radboud University Medical Center
Sponsor class: OTHER
First posted: 2005-09-28
Enrollment: 90
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: DEFINED_POPULATION
Time perspective: PROSPECTIVE

Brief summary: The purpose of this study is to compare the functional outcome of two different total knee prostheses in a prospective randomised study.


Eligibility criteria: Inclusion Criteria:

All patients on the waiting list for a TKA due to an invalidating gonarthrose as a result of osteo-arthrosis or secondary to a rheumatic disease or a trauma.

Exclusion Criteria:

* patient suffering from juvenile rheumatic disease
* patient suffering hemophilia
* patient on the waiting list for posterior stabilized TKA or hinge joint.
* patient who suffers from a lesion of the ligaments due to surgery
* patient who is legally not capable to make decisions
* patient who suffer from cancer

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Nijmegen
country: Netherlands
facility: UMC Radboud
Study officials:
affiliation: Radboud University Medical Center
name: Maarten MC de Waal Malefijt, MD
role: STUDY_CHAIR
References:
citation: Meijerink HJ, Verdonschot N, van Loon CJ, Hannink G, de Waalmalefijt MC. Similar TKA designs with differences in clinical outcome: a randomized, controlled trial of 77 knees with a mean follow-up of 6 years. Acta Orthop. 2011 Dec;82(6):685-91. doi: 10.3109/17453674.2011.636677. Epub 2011 Nov 9.
Clinical trial NCT01715337: Effects of Rehabilitation on Muscle Fibre Composition and Capillaries in Chronic Obstructive Pulmonary Disease (COPD) Patients
Official title: Effects of Pulmonary Rehabilitation on Muscle Fibre Composition and Capillaries in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Chronic Obstructive Pulmonary Disease
Keywords: muscle fibre
capillary
rehabilitation
exercise training
Lead sponsor: Schön Klinik Berchtesgadener Land
Sponsor class: OTHER
Collaborators: name: German Sport University, Cologne
First posted: 2012-10-26
Enrollment: 20
Sex: ALL
Minimum age (years): 40
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: Pulmonary rehabilitation has been established as an evidence-based and recommended therapy in patients with chronic obstructive pulmonary disease (COPD). The aim of our study is to show a potential change in muscle fibre composition and in the amount of capillaries in quadriceps muscle from pre tob post 3-week rehabilitation. Pulmonary rehabilitation includes standardised exercise training, e.g. cycling and strength training for major muscle groups.


Eligibility criteria: Inclusion Criteria:

* chronic obstructive pulmonary disease
* FEV1%pred. \< 50%

Exclusion Criteria:

* acute exacerbation
* exacerbation in the last 4 weeks

Primary outcomes:
measure: Change in the amount of capillaries in muscle fibre type I
timeFrame: change from pre (day 1) to post rehabilitation (day 21)
Secondary outcomes:
measure: Change in the amount of capillaries in muscle fibre type IIa
timeFrame: Change from pre (day 1) to post rehabilitation (day 21)
measure: Change in the cross-sectional area of muscle fibre type I
timeFrame: Change from pre (day 1) to post rehabilitation (day 21)
measure: Change in the cross-sectional area of muscle fibre type IIa
timeFrame: Change from pre (day 1) to post rehabilitation (day 21)
Other outcomes:
Locations:
city: Schönau am Königssee
country: Germany
facility: Schön Klinik Berchtesgadener Land
Study officials:
affiliation: Klinikum Berchtesgadener Land
name: Klaus Kenn, Dr. med.
role: STUDY_CHAIR
References:
Clinical trial NCT01959737: Delivery Room Skin-to-skin Study
Official title: Influence of Early SSC of Mothers and Their VLBW Infants on Maternal Sensitivity and Responsiveness, Attachment Patterns and Reactivity of HPA Axis. Molecular Characterization of SSC Influence on Stress Signaling Pathways.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Very Low Birthweight Infants
Mother Child Interaction
Preterm Infant
Keywords: reactivity of HPA axis
Lead sponsor: University of Cologne
Sponsor class: OTHER
First posted: 2013-10-10
Enrollment: 88
Sex: ALL
Minimum age (years): 10
Maximum age (years): 60
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The first hours after birth are a sensitive period for promotion of optimal mother-child-interaction and secure attachment. Maternal sensitivity and responsivness are high in the first hours after birth due to high oxytocin levels. Developing optimal mother-child-interaction is more difficult for preterm mothers because mother and child are separated after birth and the preterm infant is not able to show strong signs to promote maternal sensitivity. We hypothesize that promoting skin-to-skin contact of VLBW infants and their mothers for 60 minutes within the first hours after birth improves mother-child-interaction at 5 to 6 months corrected age. We also hypothesize that reactivity of HPA axis and molecular patterns of stress signaling pathways differ in preterm infant with or without SSC after birth.


Eligibility criteria: Inclusion Criteria:

* Birthweight \<1500g, first child, informed consent

Exclusion Criteria:

* Multiples, malformation

Primary outcomes:
measure: Maternal sensitivity and responsiveness
timeFrame: 4 to 6 moinths corrected age
Secondary outcomes:
measure: Reactivity of HPA-axis
timeFrame: 36 to 40 weeks corrected age
measure: Molecular characterization of stress signaling pathways
timeFrame: 36 to 40 weeks corrected age
Other outcomes:
Locations:
city: Cologne
country: Germany
facility: University hospital of Cologne, Department of Neonatology
Study officials:
References:
citation: Mehler K, Wendrich D, Kissgen R, Roth B, Oberthuer A, Pillekamp F, Kribs A. Mothers seeing their VLBW infants within 3 h after birth are more likely to establish a secure attachment behavior: evidence of a sensitive period with preterm infants? J Perinatol. 2011 Jun;31(6):404-10. doi: 10.1038/jp.2010.139. Epub 2010 Dec 9.
Clinical trial NCT01194037: A Phase 1b/2a Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C
Official title: A Phase 1b/2a, Open-label,Randomized, Safety, Tolerability, Dose Finding, PK/PD, and Preliminary Efficacy Study of Subcutaneous Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Chronic Hepatitis C Infection
Genotype 1
Keywords: Hepatitis C
HCV
Interferon
Hanferon
Lead sponsor: HanAll BioPharma Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2010-09-02
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is an open-label, randomized, safety, tolerability, dose-finding, PK/PD, and preliminary efficacy study of subcutaneous Hanferon™ in combination with ribavirin(RBV) in treatment-naïve subjects with genotype 1 hepatitis C.

Detailed description: The primary objective of this study is to evaluate the safety and tolerability of ascending doses of Hanferon™ in combination with ribavirin (RBV).

The secondary objective of this study is to define the PK and PD of ascending doses of Hanferon™ in combination with ribavirin(RBV). The exploratory objective of this study is to make a preliminary assessment of Hanferon™ efficacy in combination with ribavirin(RBV).

Eligibility criteria: Inclusion Criteria:

* Diagnosis of chronic hepatitis C genotype 1a or 1b
* Male or female aged 18 to 65 years, inclusive
* Compensated liver disease without evidence of cirrhosis
* No evidence of type 1 or 2 diabetes mellitus, lipodystrophy or polycystic ovary syndrome
* No history or presence of autoimmune or lymphoproliferative disease or hemoglobinopathies
* Stable medication doses for 1 month for the chronic disease if subjects have chronic diseases, including but not limited to hypertension and dyslipidemia

Exclusion Criteria:

* History of previous treatment of hepatitis C
* Currently use medication for psychiatric illness including depression, suicidal ideation, and psychosis
* History or presence of chronic liver disease
* History of drug or alcohol abuse within the past year
* Evidence of active illicit drug use
* Clinically significant abnormal electrocardiogram (ECG) or rhythm strip
* Female subject who has a positive urine pregnancy test or who is lactating

Primary outcomes:
measure: HCV RNA level
timeFrame: Week 4
Secondary outcomes:
measure: Proportion of patients who reach RVR
timeFrame: Week 4
measure: PK & PD
timeFrame: Weeks 0 and 3
Other outcomes:
Locations:
city: Los Angeles
country: United States
state: California
city: National City
country: United States
state: California
city: Miami
country: United States
state: Florida
city: Atlanta
country: United States
state: Georgia
city: Lexington
country: United States
state: Kentucky
city: New Orleans
country: United States
state: Louisiana
Study officials:
References:
Clinical trial NCT04028011: Clinical Evaluation of a Wearable Technology for the Diagnosis of Sleep Apnoea
Official title: Evaluación clínica de Una tecnología Ambulatoria Para diagnóstico Del sueño
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Obstructive Sleep Apnea
Lead sponsor: Acurable Ltd.
Sponsor class: INDUSTRY
Collaborators: name: Hospital Universitario Virgen Macarena
First posted: 2019-07-22
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients who have been referred for suspicion of sleep apnoea

Brief summary: This trial will aim to test a new wearable device for the diagnosis of Sleep Apnoea.

Detailed description: This clinical trial will test a new wearable device for the diagnosis of Sleep Apnoea against Multi-channel polygraphy and Polysomnography.

Eligibility criteria: Inclusion Criteria:

* Patients who have been referred to a sleep clinic due to suspicion of sleep apnoea.
* patients between the age of 18 yo and 80 yo

Exclusion Criteria:

* who are not fluent in Spanish, or who have special communication needs.
* Known allergy to the adhesive dressing.
* patients with physical or mental impairments who would not be able to use the new technology on their own.
* patients with very loose/saggy skin in the neck area which would unavoidably result on AcuPebble swinging if moving the neck.
* patients with pacemakers or who have any type of implanted electronic device

Primary outcomes:
measure: Sensitivities and Specificity for diagnosis of sleep apnoea studies with novel wearable device
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Seville
country: Spain
facility: Hospital Virgen Macarena Sevilla
Study officials:
affiliation: Hospital Universitario Virgen Macarena
name: Jesus Fernando Sanchez Gomez, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05238311: Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)
Study type: EXPANDED_ACCESS
Overall status: NO_LONGER_AVAILABLE
Conditions: Multiple Myeloma
Keywords: refractory
relapsed
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2022-02-14
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT

Brief summary: Provide pre-approval single-patient Expanded Access (Compassionate Use) of elranatamab for patients with relapsed/refractory multiple myeloma

Detailed description: In Expanded Access, treating physicians are the Sponsors

Expanded Access requests from treating physicians should be directed to www.pfizercares.com Availability will depend on location.

Eligibility criteria: Must have relapsed/refractory multiple myeloma (RRMM) and be refractory to at least one immunomodulatory drug, one proteasome inhibitor and one anti-CD38 antibody. Must have evidence of disease progression after last therapy. Must have exhausted all available treatment options accessible as local standard of care and not be eligible for participation in any ongoing clinical trial. Additional eligibility criteria may be required.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: